Related Experiment Videos
Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in
Si-Jie Chen1,2,3, Shi-Wei Yue1,2,3, Yun-Pu Zhang1,2,3
1Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract:
Cancer metabolism is characterized by profound reprogramming, yet the mechanisms enabling rapid and precise adaptation remain incompletely understood. This review establishes post-translational modifications (PTMs) as the central processing unit of oncogenic metabolic reprogramming. PTMs execute a conserved three-tiered regulatory logic: they interpret oncogenic and environmental signals, command metabolic flux, and cement malignant phenotypes through epigenetic and feedback mechanisms. We systematically demonstrate how this PTM-driven logic governs key pillars of cancer metabolism-glucose, lipid, amino acid, and nucleotide utilization-and extends its command to critical cell fate execution programs, including mitochondrial dynamics, autophagy, and ferroptosis. Furthermore, we delineate how PTMs act as master regulators of immunometabolic reprogramming within the tumor microenvironment (TME), directly linking tumor metabolism to T cell exhaustion, myeloid cell polarization, and immune evasion. By integrating recent advances on the determinants and crosstalk of PTM networks, we describe how metabolic plasticity and heterogeneity are encoded at the PTM level, with metabolic gradients shaping distinct "PTM geographies" within tumors. Finally, we translate these insights into clinical prospects, highlighting PTM-based biomarkers, PTM-targeted drugs and emerging therapeutic strategies, including targeted protein degradation, PTM-targeted vaccines and dietary interventions. Deciphering this PTM-encoded program reveals a new landscape of therapeutic vulnerabilities, shifting the paradigm toward rationally targeting the fundamental computational logic that sustains tumors.
Insights
Post-translational modifications (PTMs) are central to cancer metabolism reprogramming, interpreting signals to control metabolic flux and malignant phenotypes. This review highlights PTMs as key regulators of cancer cell metabolism and therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cancer cells exhibit significant metabolic reprogramming for survival and proliferation.
- The precise mechanisms governing this rapid metabolic adaptation in cancer remain incompletely understood.
Purpose of the Study:
- To establish post-translational modifications (PTMs) as the central regulatory unit of oncogenic metabolic reprogramming.
- To systematically review the role of PTMs in governing cancer metabolism and cell fate.
- To explore the clinical implications of PTMs in cancer therapy.
Main Methods:
- Systematic review of literature on PTMs and cancer metabolism.
- Integration of advances in PTM network determinants and crosstalk.
- Analysis of PTMs' role in metabolic plasticity and tumor microenvironment.
Main Results:
- PTMs interpret oncogenic signals, control metabolic flux (glucose, lipid, amino acid, nucleotide utilization), and cement malignant phenotypes.
- PTMs regulate critical cell fate programs like mitochondrial dynamics, autophagy, and ferroptosis.
- PTMs are master regulators of immunometabolic reprogramming within the tumor microenvironment, influencing immune evasion.
Conclusions:
- PTMs encode metabolic plasticity and heterogeneity, creating distinct "PTM geographies" within tumors.
- PTMs represent promising targets for novel cancer biomarkers and therapies, including targeted protein degradation and PTM-targeted vaccines.
- Targeting PTMs offers a paradigm shift towards rationally targeting tumor-sustaining computational logic.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...